Learn more about our Glypican-1 (GPC-1) antibody as a targeted therapy for delivering a radioactive payload to cancer cells.
The evidence for GPC-1 being a key target in cancer therapy continues to expand rapidly. This includes recent publications with our collaborator, Professor Kris Thurecht as part of the ARC Training Centre for Innovation in Biomedical Imaging Technology at UQ’s Centre for Advanced Imaging. These recent papers outline:
1. Clinical development strategies and considerations for the development of an anti-GPC-1 antibody Miltuximab®
2. The challenges of using antibodies to treat Glioblastoma
3. PET-CT imaging in Glioblastoma preclinical models using different Miltuximab® formats.
We look forward to continuing this collaboration and developing new anti-GPC-1 therapies as part of the new ARC Hub for Advanced Manufacturing of Targeted Radiopharmaceuticals (AMTAR).
To date, we have published 17 papers demonstrating the biology and utility of this unique and extremely interesting molecular target.